Baxter International (BAX)

• Market cap: $17.3B
• 1 day: 1.14%
• 5 days: 9.24%
• 1 month: 7.43%
• 3 months: 2.52%
• 6 months: -6.52%
• Year to date: 15.58%
• 1 year: -19.91%
• 5 years: -63.50%
• 10 years: -50.73%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 60,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2.67% more ownership

Funds ownership: 91.52% [Q3] → 94.19% (+2.67%) [Q4]

12% less funds holding

Funds holding: 877 [Q3] → 773 (-104) [Q4]

15% less call options, than puts

Call options by funds: $91.6M | Put options by funds: $108M

21% less capital invested

Capital invested by funds: $17.7B [Q3] → $14B (-$3.65B) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

26% less repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 324

40% less first-time investments, than exits

New positions opened: 98 | Existing positions closed: 162

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 3% upside
• Avg. target: $37 8% upside
• High target: $39 15% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

JP Morgan Robbie Marcus 60% 1-year accuracy 12 / 20 met price target	6% upside $36	Neutral Maintained	21 Feb 2025
Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target	15% upside $39	Overweight Reinstated	20 Feb 2025
Citigroup Joanne Wuensch 73% 1-year accuracy 35 / 48 met price target	3% upside $35	Neutral Maintained	11 Dec 2024